How Do You Know It’s Psoriasis? Here Are The Signs And Symptoms You Should Look For
More than 125 million people worldwide suffer from some form of psoriasis. If you’ve struggled with your skin health this ...
GlobalData on MSN10d
Vanda and AnaptysBio link for generalised pustular psoriasis therapy
Vanda Pharmaceuticals and AnaptysBio have announced an exclusive worldwide licence agreement to develop and commercialise the fully humanised immunoglobulin G4 (IgG4) antibody, imsidolimab, to treat ...
The American Journal of Managed Care10d
GPP Flares Linked to Increased Hospitalizations, Health Care Costs, Study Finds
New research highlights the significant health care resource utilization burden of generalized pustular psoriasis (GPP), ...
Vanda Pharmaceuticals And Anaptys Announce Exclusive Global License Agreement For Vanda To Develop And Commercialize Imsidolimab, An IL-36R Antagonist
Imsidolimab has successfully completed two global Phase 3 studies in Generalized Pustular Psoriasis <li /> Vanda expects to immediately ...
Le Lézard9d
Boehringer Canada Announces Availability of SPEVIGO® for expanded indication in Canada
Generalized pustular psoriasis (GPP) is a rare, chronic, heterogenous neutrophilic inflammatory disease associated with skin and systemic symptoms, such as fever, pain, and fatigue.1,2,3,4SPEVIGO's ...
Business Insider11d
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist
evaluating the safety and efficacy of imsidolimab in patients with Generalized Pustular Psoriasis (GPP). GPP is a rare skin disorder often caused by mutations in the IL36RN gene that codes for a ...